SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Clinical Alliance for Research & Education - Infectious Diseases, LLC.

Status and phase: Unknown; Phase 4

Conditions: Lipodystrophy; HIV Infections

Treatments: Drug: ritonavir (Norvir); Drug: atazanavir (Reyataz)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00426296

COL102060

Details and patient eligibility

About

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Full description

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA <50 copies/mL at entry

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
• Viral load <50 copies/ml

Exclusion criteria

• Viral load >50 copies/ml
• Having taken more than one antiretroviral regimen

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)